Answers are grounded in this paper and cite their sources.
Background Hematologic recovery after treatment varies substantially among patients with aplastic anemia (AA). This exploratory clinical multi-omics study aimed to characterize gut microbial and metabolomic features associated with hemoglobin improvement in patients with AA. Methods Nineteen patients with AA who received kidney-nourishing and marrow-benefiting traditional Chinese medicine combined with conventional Western medical treatment were included. According to hematologic response at approximately 6 months, patients were classified as responders ( n = 14) or non-responders ( n = 5). Paired fecal and serum samples collected before and after treatment were analyzed using 16S rRNA sequencing and untargeted metabolomics. Hb_change, defined as post-treatment hemoglobin minus baseline hemoglobin, was used as the primary clinical variable. Associations between omics features and Hb_change were assessed using Spearman correlation with Benjamini–Hochberg correction. Leave-one-out analysis, bootstrap confidence intervals, baseline Hb-adjusted models, and paired longitudinal analyses were used to further examine selected associations. Results Hb_change was greater in responders than in non-responders (31.5 vs. 10.0 g/L, p = 0.006). In the pretreatment microbiome, Methyloversatilis was negatively correlated with Hb_change (rho = −0.712, p = 0.000627, q = 0.0881), whereas Shuttleworthia was positively correlated with Hb_change (rho = 0.703, p = 0.000779, q = 0.0881). For Methyloversatilis, leave-one-out correlations remained negative (rho range, −0.813 to −0.673), the bootstrap 95% confidence interval was −0.883 to −0.340, and the baseline Hb-adjusted coefficient was −8.34 g/L per 1-SD increase (95% CI, −13.89 to −2.80; p = 0.00567). In the metabolomic analyses, the post-treatment fecal feature putatively annotated as N-Acetylgalactosamine_6-sulfate and the serum features Quinic acid and Proline, together with features putatively annotated as PC(37:4) and 4-(Thiophen-2-yl)-6-(trifluoromethyl)pyrimidin-2-ol, showed nominal positive associations with Hb_change, but none met q < 0.1 in the corresponding full-feature analyses. Longitudinal microbiome analyses identified FDR-supported within-patient changes, whereas no fecal or serum metabolomic feature met q < 0.1 in the longitudinal analyses. Conclusions Pretreatment gut microbial features showed FDR-supported associations with hemoglobin improvement, while the highlighted fecal and serum metabolic features showed nominal associations that did not remain significant after full-feature multiple-testing correction. These findings are exploratory and require validation in larger independent cohorts.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: